M. Helm

Phenotypic HIV-1 Resistance Correlates with Treatment Outcome of Nelfinavir Salvage Therapy

B. Schmidt, H. Walter, K. Korn, 1999, Antiviral therapy.

Variant of hepatitis B virus with primary resistance to adefovir.

M. Helm, J. Rockstroh, H. Will, 2006, The New England journal of medicine.

Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors

M. Helm, M. Eichenmüller, B. Fleckenstein, 2005, AIDS.

Differential effects of P-class versus other CpG oligodeoxynucleotide classes on the impaired innate immunity of plasmacytoid dendritic cells in HIV type 1 infection.

B. Schmidt, K. Korn, M. Helm, 2010, AIDS research and human retroviruses.

Nonresponse to adefovir: host or virus dependent?

M. Helm, W. Gerlich, O. Schildgen, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Selection and Counterselection of the rtI233V Adefovir Resistance Mutation during Antiviral Therapy

M. Helm, J. Rockstroh, H. Sirma, 2009, Journal of Clinical Microbiology.

Chronic Immune Activation in HIV-1 Infection Contributes to Reduced Interferon Alpha Production via Enhanced CD40:CD40 Ligand Interaction

B. Schmidt, M. Helm, T. Harrer, 2012, PloS one.

No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual.

B. Schmidt, H. Walter, K. Korn, 2002, Journal of acquired immune deficiency syndromes.

No Evidence for Persistence of Multidrug‐Resistant Viral Strains After a 7‐Month Treatment Interruption in an HIV‐1‐Infected Individual

B. Schmidt, H. Walter, K. Korn, 2002 .

Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study.

B. Schmidt, H. Walter, K. Korn, 2007, European journal of medical research.